153 results
8-K
EX-99.1
ATRX
Adhera Therapeutics, Inc.
16 Aug 00
Current report
12:00am
of Nastech's Executive Committee. "This
opportunity is exemplified by Atossa's breast cancer risk assessment test, and
Nastech's key programs in pain … , is focused on the development of a
proprietary platform of diagnostics and treatments related to breast cancer risk
assessment and therapeutics and other
CORRESP
ATRX
Adhera Therapeutics, Inc.
10 Sep 10
Correspondence with SEC
12:00am
value that results from these calculations based on our assessment of the probability that the exercise price will adjust. Our probability … assumptions are based on the facts and circumstances that exist as of the reporting date and are based on our assessment of factors such as whether we plan
S-8
EX-23.1
ATRX
Adhera Therapeutics, Inc.
12 Jul 06
Registration of securities for employees
12:00am
assessment of the
effectiveness of internal control over financial reporting as of December 31,
2005, and the effectiveness of internal control over
S-8
EX-23.1
s5av494j
27 Jul 05
Registration of securities for employees
12:00am
S-3MEF
EX-23.1
vhh5yw25orsaged2ou84
25 Aug 05
Registration of additional securities for an S-3
12:00am
8-K
5x4jhtbl29c90qr roj
16 Aug 00
Current report
12:00am
8-K
EX-99.1
34afo3ma hcieqrs4rw
10 Mar 04
Other events
12:00am
8-K
EX-99.1
kmkfxce y0bgol3
17 Jul 03
Cytyc Acquires Exclusive Patent Rights to Nastech’s Mammary Aspirate Device
12:00am
8-K
EX-10.1
uuflobuekjg16qt8ux11
15 Oct 02
Acquisition or disposition of assets
12:00am
8-K
EX-99.1
w9o7yp
20 Sep 06
Regulation FD Disclosure
12:00am
10QSB
goj15ryhhkl wzt
1 Nov 96
Quarterly report (small business)
12:00am